John Miranda
The personalized medicine model seeks to identify unique characteristics within each patient that can serve as a basis for disease characterization and specialized treatment rather than managing those with a specific diagnosis in accordance with established guidelines. Hemoglobin A1C, fructosamine, and anhydroglucitol are among the circulating biomarkers of glycaemia that are utilized in the medical management of diabetes and are discussed in this article. The areas in which biomarker results do not correlate with anticipated results based on actual mean glycaemia are the focus of the discussion. Inconstancy among genuine and expected aftereffects of the different biomarker tests addresses chances to distinguish already vague subcategories of diabetes and gatherings of patients that fit into these subcategories. Finally, research areas that would further advance the field of personalized diabetes medicine are suggested for these subcategories.
Keywords1, 5-Anhydroglucitol; Diabetes biomarkers; Glycation gap; Hemoglobin A1C variability; Hemoglobin glycation index; Personalized medicine
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi